ReviewJournal of clinical laboratory analysis2022
An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
Review in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of SARS-CoV-2 Vaccines on Sperm Quality: Systematic Review.JMIR public health and surveillance · 2023Pooled it
- Single-cell transcriptomics reveals pediatric immune responses to COVID-19 vaccination.iScience · 2026Article
- Viral Clearance: Safety and Efficiency of Biopharmaceuticals.Therapeutic innovation & regulatory science · 2026Review
- AddaVax-Adjuvanted Inactivated Vaccine Confers Protection Against Listeria monocytogenes Challenge in Mice.Current microbiology · 2026Article
- Article
- Article
- Exploring Immune Responses to SARS-CoV-2: Insights from Sinopharm (BBIBP-CorV)-Vaccinated Individuals in a Group of Venezuelan Admixed Volunteers.Biomedicines · 2025Article
- Long-term immune changes after COVID-19 and the effect of BCG vaccination and latent infections on disease severity.Clinical & translational immunology · 2025Article
- Delivery and adjuvant: liposomes for SARS-CoV-2 vaccines.Biotechnologia · 2025Review
- COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.AIMS neuroscience · 2025Review
- Article
- Review
- Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial.Clinical and experimental vaccine research · 2024Article
- Regulation of protein thermal stability and its potential application in the development of thermo-attenuated vaccines.Engineering microbiology · 2024Article
- Review
- Single cell phototransfection of mRNAs encoding SARS-CoV2 spike and nucleocapsid into human astrocytes results in RNA dependent translation interference.Frontiers in drug delivery · 2024Article
- Vogt-Koyanagi-Harada Disease and COVID.Journal of clinical medicine · 2023Review
- Review
- Evaluation of local and systemic side effects of Turkovac vaccine in adults.Turkish journal of medical sciences · 2023Article
- Inactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin.Immunology letters · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID-19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID-19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS-CoV-2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS-CoV-2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.